Yunchang Meng

Sichuan University — China

Medicine · Health Sciences

3h-index21citations10works2.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(7), Lung Cancer Diagnosis and Treatment(5), Cancer Cells and Metastasis(2), Lung Cancer Treatments and Mutations(2), Immunotherapy and Immune Responses(2)

Publications10 total

Tumor immune microenvironment analysis in different pathologic responses to neoadjuvant immunotherapy combined with chemotherapy in non-small cell lung cancer
Translational Lung Cancer Research·2025· 3 citedOpen Access
Lymph nodes metastatic burden as a prognosticator for advanced non-small cell lung cancer: a real-world study
Journal of Thoracic Disease·2025Open Access
Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials
Clinical & Translational Oncology·2024
Immunohistochemistry identifies E-cadherin, N-cadherin and focal adhesion kinase (FAK) as predictors of stage I non-small cell lung carcinoma spread through the air spaces (STAS), and the combinations as prognostic factors
Translational Lung Cancer Research·2024· 8 citedOpen Access
Established the prediction model of early‐stage non‐small cell lung cancer spread through air spaces (STAS) by radiomics and genomics features
Asia-Pacific Journal of Clinical Oncology·2024· 5 citedOpen Access
Efficacy and safety of perioperative, neoadjuvant or adjuvant immunotherapy alone or in combination chemotherapy in early-stage non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
Journal of Clinical Oncology·2024· 1 cited
Association of N-adhesin and focal adhesion kinase with frequency of tumor spread through the airspace (STAS) in stage I lung carcinoma and correlation with recurrence.
Journal of Clinical Oncology·2024
Efficacy and Safety of Neoadjuvant, Adjuvant, and Perioperative Immune Checkpoint Inhibitors Single Agent or with Chemotherapy in Resectable NSCLC: Indirect Comparison and Clinicopathological Impact
2024· 1 citedOpen Access
Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials
Therapeutic Advances in Medical Oncology·2024· 3 citedOpen Access
Comparing the efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis
2023Open Access

Frequent Co-authors

Ranpu Wu(7), Yanzhuo Gong(6), Zhaofeng Wang(6), Hongbing Liu(6), Zhangxuan Chen(4), Huijuan Li(4), Qingfeng Zhang(4), Yimin Wang(3), Chuling Li(3), Yong Song(3), Tangfeng Lv(3), Xinjing Li(3), Yingshui Yao(2), Hongbing Liu(2), Hedong Han(2), Suhua Zhu(2), Leilei Liu(1), Qingfeng Zhang(1), Xinjing Li(1), Huijuan Li(1)